Life Sciences in Vienna

12.2 bn
Sales / Year
Source: Vienna Life Science Report 2017/18 (Data: 2017) More Information


Rudolf Heintel Medizintechnik übernimmt Odelga med.

Das österreichische Familienunternehmen Rudolf Heintel Gesellschaft m.b.H. startet in sein Jubiläumsjahr zum...

Hookipa Appoints Michael A. Kelly as Independent Director

HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics targeting infectious diseases...

All news

Twitter @lifesciencevie



Pharmig Academy: Government Affairs & Lobbying für die pharmazeutische Industrie

Die Pharmig freut sich auf Ihre Teilnahme.


TU Wien: i²c Networking Friday 2019

“Innovation & Entrepreneurship Summit” of the TU Wien

24.2. - 25.2.2019


2019 MCAA General Assembly and Conference

6th general assembly and conference of the Marie Curie Alumni Association: Research beyond the information age


Pharmig Academy: Zertifikatslehrgang Pharmarecht & Compliance, Modul 1

Grundlagen & praktischer Anwendungsbereich

All events

Why Vienna?

Philipp von Lattorff - Boehringer Ingelheim
(C) Boehringer Ingelheim / Marion Carniel

Political stability is a major factor when considering major investments in a country. Austria scores very highly in that regard, as it does in terms of infrastructure and standard of living. Without a doubt, however, one of the most important considerations for a research-driven company is research subsidies. This also played a decisive role in the decision to invest 700 million euros in the construction of our new biopharmaceutical production facility in Vienna. We are looking for highly qualified candidates to fill the 500 new positions, created for this project, and attach great importance for that reason to the training and qualifications of potential employees.

Philipp von Lattorff
Managing Director at Boehringer Ingelheim RCV GmbH & Co KG